Group 1 - On August 1, the Hong Kong stock market saw a net inflow of 12.207 billion HKD from northbound trading, with 5.575 billion HKD from the Shanghai Stock Connect and 6.632 billion HKD from the Shenzhen Stock Connect [2] - The most bought stocks included the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and Xiaomi Group-W (01810), while the most sold stocks were Innovent Biologics (01801), Alibaba-W (09988), and SMIC (00981) [2][8] - Xiaomi Group-W reported over 30,000 vehicle deliveries in July, attributed to increased production capacity, with expectations of 400,000 to 500,000 vehicle sales by 2025 [6] Group 2 - In the technology sector, Tencent (00700), Meituan-W (03690), and Kuaishou-W (01024) saw net inflows of 8.36 billion, 7.66 billion, and 2.02 billion HKD respectively, while Alibaba-W faced a net outflow of 2.02 billion HKD [7] - InnoCare Pharma (02577) received a net inflow of 3.63 billion HKD after being listed as a partner by NVIDIA for its 800V DC power architecture, which is designed for AI data centers [7] - The overall sentiment in the Hong Kong market remains positive, with expectations of a structural uptrend driven by improving fundamentals and policy outlook [6][7]

8月1日上榜港股通成交活跃榜个股中，英诺赛科为近一个月首次上榜。 证券时报·数据宝统计显示，8月1日港股通（包括沪市港股通及深市港股通）成交活跃股合计成交387.67 亿港元，占当日港股通成交金额的29.03%，净买入金额90.16亿港元。 上榜的成交活跃股中，腾讯控股成交额为54.12亿港元，成交金额居首；其次是英诺赛科、阿里巴巴- W，成交金额分别为43.91亿港元、43.90亿港元。 8月1日港股通成交活跃股榜单 | 证券 | 证券简称 | 成交金额（亿 | 净买入金额（亿 | 近一个月上榜 | 最新收盘价 | 日涨跌幅 | | --- | --- | --- | --- | --- | --- | --- | | 代码 | | 港元） | 港元） | 次数 | （港元） | （%） | | 00700 | 腾讯控股 | 54.12 | 8.36 | 23 | 535.000 | -2.73 | | 00981 | 中芯国际 | 15.78 | -1.77 | 23 | 50.050 | -2.05 | | 01810 | 小米集团 | 39.96 | 10.99 | 23 | 53.400 | 0.4 ...

8月1日恒生指数下跌1.07%，南向资金全天合计成交金额为1335.36亿港元，其中，买入成交728.72亿港 元，卖出成交606.64亿港元，合计净买入金额122.07亿港元。具体来看，港股通（深）累计成交金额 507.42亿港元，买入成交286.87亿港元，卖出成交220.55亿港元，合计净买入金额66.32亿港元；港股通 （沪）累计成交金额827.94亿港元，买入成交441.85亿港元，卖出成交386.09亿港元，合计净买入金额 55.75亿港元。 8月1日南向资金成交活跃股 | 代码 | 简称 | 成交金额（万港元） | 成交净买入（万港元） | 今日涨跌幅（%） | | --- | --- | --- | --- | --- | | 02800 | 盈富基金 | 376296.66 | 374441.50 | -1.11 | | 02828 | 恒生中国企业 | 221455.60 | 171972.10 | -0.95 | | 01810 | 小米集团-W | 399608.65 | 109922.43 | 0.47 | | 03033 | 南方恒生科技 | 185424.26 | 85558.9 ...

Group 1 - China Biopharmaceutical announced a successful collaboration progress with Merck on LM-299, expecting to receive a $300 million technology transfer milestone payment soon [1] - The technology transfer for LM-299 was completed in July 2025, with Merck confirming the milestone payment in the third quarter [1] - CSPC Pharmaceutical reached an exclusive licensing agreement with Madrigal for the GLP-1 receptor agonist SYH2086, with a total deal value of up to $20.75 billion [2] Group 2 - Eli Lilly's drug Mounjaro (tirzepatide injection) received approval from China's National Medical Products Administration for a new indication to improve blood sugar control in adults with type 2 diabetes [3] - Hualan Pharmaceutical expects a profit of approximately RMB 1.184 billion for the first half of the year, following the successful transfer of commercialization tasks for Huataning [4] - WuXi AppTec reported a 101.92% increase in net profit to RMB 8.561 billion for the first half of the year, with revenue growth of 20.64% to RMB 20.799 billion [5] Group 3 - Heng Rui Medicine signed a collaboration agreement with GSK to advance innovative therapies in respiratory, autoimmune, inflammation, and oncology fields, with a potential total value of approximately $12 billion [6][7] - GSK will pay Heng Rui a $500 million upfront payment, with potential future milestone payments based on successful development and sales [7]

Group 1 - Southbound funds recorded a net inflow of HKD 12.207 billion, marking the fourth consecutive day of net inflows exceeding HKD 10 billion [1] - Notable net purchases included the Tracker Fund of Hong Kong (HKD 3.744 billion), China Enterprises Index (HKD 1.72 billion), and Xiaomi Group (HKD 1.099 billion) [1] - Southbound funds have consistently net purchased Tencent for 7 days, totaling HKD 3.5417 billion, and Xiaomi for 6 days, totaling HKD 4.13539 billion [3] Group 2 - Xiaomi Group's chairman Lei Jun announced that the company delivered over 30,000 vehicles in July and plans to open 18 new stores in August, expanding its presence to 352 stores across 97 cities [4] - InnoCare Pharma announced a partnership with NVIDIA to promote the large-scale implementation of an 800 VDC power architecture in AI data centers, which significantly enhances system efficiency and reliability [4] - Stone Pharmaceutical completed a transaction with Madrigal involving a GLP-1 small molecule drug with an upfront payment of USD 120 million and potential milestone payments of up to USD 1.955 billion [4] Group 3 - The Hong Kong Monetary Authority's stablecoin licensing regime officially took effect on August 1, with expectations of a limited number of initial licenses being issued [5] - BlackRock reduced its stake in Innovent Biologics from 5.19% to 4.69% as the company registered a Phase II clinical trial for IBI363, indicating confidence in its new generation immunotherapy [5] - UBS forecasts a 36% year-on-year revenue growth for Innovent Biologics in the first half of the year, projecting the company to achieve breakeven [5]

Group 1 - On August 1, the Hong Kong stock market saw a net inflow of 12.207 billion HKD from northbound trading, with 5.575 billion HKD from the Shanghai Stock Connect and 6.632 billion HKD from the Shenzhen Stock Connect [2] - The most bought stocks included the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and Xiaomi Group-W (01810), while the most sold stocks were Innovent Biologics (01801), Alibaba-W (09988), and SMIC (00981) [2] - The Tracker Fund of Hong Kong received a net inflow of 37.44 billion HKD, Hang Seng China Enterprises received 17.19 billion HKD, and Southern Hang Seng Technology (03033) received 8.55 billion HKD [5] Group 2 - Xiaomi Group-W (01810) saw a net inflow of 8.55 billion HKD, with the chairman announcing that July's car deliveries exceeded 30,000 units due to increased production capacity [6] - Tencent (00700), Meituan-W (03690), and Kuaishou-W (01024) received net inflows of 8.36 billion HKD, 7.66 billion HKD, and 2.02 billion HKD respectively, while Alibaba-W (09988) faced a net outflow of 2.02 billion HKD [6] - Innovent Biologics (02577) received a net inflow of 3.63 billion HKD after being listed as a partner by NVIDIA for its 800V direct current power architecture [7] Group 3 - Guotai Junan International (01788) experienced a net outflow of 48.99 million HKD amid the implementation of the stablecoin regulatory framework in Hong Kong [8] - Other stocks that saw net inflows included CSPC Pharmaceutical Group (01093) with 2.52 billion HKD and Giant Legend (06683) with 6.55 million HKD, while Innovent Biologics (01801) and SMIC (00981) faced net outflows of 4.02 billion HKD and 1.77 billion HKD respectively [8]

Group 1 - On August 1, 2025, InnoCare Pharma (02577), Tencent Holdings (00700), and Alibaba Group-W (09988) ranked as the top three companies by trading volume in the Southbound Stock Connect, with transaction amounts of 3.333 billion, 3.023 billion, and 2.736 billion respectively [1] - In the Southbound Stock Connect, Tencent Holdings (00700), Yingfu Fund (02800), and Southern Hang Seng Technology (03033) were the top three companies by trading volume, with transaction amounts of 2.389 billion, 2.076 billion, and 1.854 billion respectively [1] Group 2 - The top ten active companies in the Southbound Stock Connect included InnoCare Pharma (02577) with a transaction amount of 3.333 billion and a net buying amount of +320 million, Tencent Holdings (00700) with 3.023 billion and +102 million, and Alibaba Group-W (09988) with 2.736 billion and -416 million [2] - In the Southbound Stock Connect, Tencent Holdings (00700) had a transaction amount of 2.389 billion and a net buying amount of +734 million, Yingfu Fund (02800) had 2.076 billion and +2069 million, and Southern Hang Seng Technology (03033) had 1.854 billion and +856 million [2]

Investment Rating - The report maintains a positive outlook on the pharmaceutical and biotechnology industry, emphasizing the transition from "Made in China" to "Created in China" for innovative drugs [10]. Core Insights - The report highlights that domestic innovative drugs are gaining global competitiveness and are currently in the first and second stages of international expansion, primarily through licensing agreements and partnerships [10][12]. - The report identifies key areas of focus for investment, including PD-(L)1 plus, ADCs, and GLP-1 drugs, which are expected to drive future growth and business development (BD) opportunities [10][51]. Summary by Sections Section 1: Transition from "Manufacturing" to "Innovation" - The policy reforms initiated in 2015 have stimulated a shift from generic to innovative drug development in China, with significant increases in R&D investment since 2018 [19][21]. - The number of First-in-Class (FIC) drugs developed in China has risen from 9 in 2015 to 120 in 2024, indicating a substantial increase in innovation [25][26]. Section 2: Continued BD Opportunities - PD-(L)1 plus is identified as a cornerstone for next-generation cancer treatments, with significant demand and potential for new products [51]. - The report notes that ADCs are transitioning towards more differentiated targets, focusing on unmet clinical needs, with promising candidates like PD-L1, DLL3, and EGFR [51]. - The GLP-1 market is experiencing rapid growth, with a focus on multi-target, oral, combination, and long-acting formulations [51]. Section 3: Investment Recommendations - For PD-(L)1 plus, companies such as Kangfang Biotech, Shansheng Pharmaceutical, and Junshi Biosciences are recommended for investment due to their strong pipelines [5]. - In the ADC space, companies like Fuhong Hanlin and Zai Lab are highlighted for their potential in addressing unmet clinical needs [5]. - In the GLP-1 sector, firms such as Borui Pharmaceutical and Zai Lab are noted for their promising developments [5].

Core Viewpoint - The report from Citi indicates that CSPC Pharmaceutical Group (01093) is expected to see a resurgence in core profit growth starting in 2026, driven by its 10 existing innovative brands and over 30 innovative products set to launch by 2028 [1] Group 1 - Citi has raised the target price for CSPC from HKD 13.8 to HKD 17.4, reaffirming a strong buy rating [1] - The company completed a transaction with biopharmaceutical firm Madrigal involving the GLP-1 small molecule drug SYH2086, with an upfront payment of USD 120 million and potential milestone payments totaling USD 1.955 billion, plus sales royalties calculated as a percentage [1] - Revenue forecasts for CSPC for 2025 to 2027 have been increased by 1.6%, 14.3%, and 3% respectively, while net profit forecasts have been raised by 11.8%, 73.3%, and 11.6% to reflect completed and potential licensing projects [1]

Core Viewpoint - The report from Citi indicates that CSPC Pharmaceutical Group (01093) is expected to see a resurgence in core profit growth starting in 2026, driven by its 10 existing innovative brands and over 30 innovative products set to launch before 2028. The target price has been raised from HKD 13.8 to HKD 17.4, maintaining a strong buy rating [1] Group 1 - CSPC has completed a transaction with biopharmaceutical company Madrigal involving the GLP-1 small molecule drug SYH2086, with an upfront payment of USD 120 million and potential milestone payments totaling USD 1.955 billion, plus sales royalties calculated as a percentage [1] - The revenue forecasts for CSPC for 2025 to 2027 have been adjusted upwards by 1.6%, 14.3%, and 3% respectively, reflecting the assumptions regarding completed and potential licensing projects [1] - The net profit forecasts for CSPC have been increased by 11.8%, 73.3%, and 11.6% for the same period, indicating a positive outlook based on the company's strategic developments [1]